140 related articles for article (PubMed ID: 10510219)
1. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.
Gutteridge DH; Ward LC; Stewart GO; Retallack RW; Will RK; Prince RL; Criddle A; Bhagat CI; Stuckey BG; Price RI; Kent GN; Faulkner DL; Geelhoed E; Gan SK; Vasikaran S
J Bone Miner Res; 1999 Oct; 14 Suppl 2():79-84. PubMed ID: 10510219
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
3. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate resistance in Paget's disease of bone.
Joshua F; Epstein M; Major G
Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
Wimalawansa SJ; Gunasekera RD
Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous pamidronate therapy on Paget's disease of bone.
Bombassei GJ; Yocono M; Raisz LG
Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
[TBL] [Abstract][Full Text] [Related]
8. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
9. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
11. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
12. [A single infusion of Pamidronate (APD) in Paget's disease of bone].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the bisphosphonate APD in the control of Paget's bone disease.
Mautalen CA; Gonzalez D; Ghiringhelli G
Bone; 1985; 6(6):429-32. PubMed ID: 4096879
[TBL] [Abstract][Full Text] [Related]
15. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
Tucci JR; Bontha S
Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
[TBL] [Abstract][Full Text] [Related]
16. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
18. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
Bone; 1994; 15(3):261-7. PubMed ID: 8068446
[TBL] [Abstract][Full Text] [Related]
19. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
20. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
